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Obesity is deﬁned as the excess accumulation of intra-abdominal body fat, resulting in a state of chronic, low-grade
proinﬂammation that can directly contribute to the development of insulin resistance. Pentraxin 3 (PTX3) is an acute-phase
protein that is expressed by a variety of tissue and cell sources and provides an anti-inﬂammatory property to downregulate the
production of proinﬂammatory cytokines, in particular interleukin-1 beta and tumor necrosis factor alpha. Although PTX3
may therapeutically aid in altering the proinﬂammatory milieu in obese individuals, and despite elevated expression of
PTX3 mRNA observed in adipose tissue, the circulating level of PTX3 is reduced with obesity. Interestingly, aerobic
activity has been demonstrated to elevate PTX3 levels. Therefore, the purpose of this review is to discuss the therapeutic
potential of PTX3 to positively regulate obesity-related inﬂammation and discuss the proposition for utilizing aerobic
exercise as a nonpharmacological anti-inﬂammatory treatment strategy to enhance circulating PTX3 concentrations in
obese individuals.
1. Introduction
Obesity is a state of chronic, low-grade proinﬂammation that
derives from the excess inﬁltration and accumulation of neu-
trophils and resident macrophages within the adipose tissue
[1–3]. This proinﬂammatory state directly contributes to
the increased risk and pathology of obesity-related metabolic
dysfunction, including insulin resistance and the subsequent
development of type 2 diabetes mellitus [4, 5]. Alarmingly,
adult obesity prevalence rates in the United States have
signiﬁcantly increased from 30.5% to 37.7% since the turn
of the century [6], highlighting the need to identify potential
therapeutic approaches that attenuate obesity-related
proinﬂammatory proﬁles.
Counter to obesity-related inﬂammation, pentraxin 3
(PTX3) is an acute-phase protein that is induced in
response to proinﬂammatory stimulation by a variety of
cell types, including adipocytes, neutrophils, monocytes,
and macrophages [7–9]. With obesity, PTX3 mRNA
expression is elevated in adipose tissue and is positively asso-
ciated with the mRNA expression of the proinﬂammatory
cytokines interleukin-1 beta (IL-1β) and tumor necrosis
factor alpha (TNF-α) [10, 11]. However, our laboratory and
others have shown that circulating concentrations of PTX3
are reduced in obese individuals [11–13], suggesting that
circulating PTX3 concentrations are dysregulated during
obesity. Recent studies further demonstrate that PTX3
elicits the production of anti-inﬂammatory cytokines IL-
10 and transforming growth factor beta (TFG-β) while
downregulating the proinﬂammatory response [14–16].
Therefore, the purpose of this review is to discuss the
potential factors contributing to obesity-related PTX3
dysregulation. Furthermore, this review will address the
therapeutic potential of PTX3 to improve obesity-related
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inﬂammatory imbalance, and because of the reported ele-
vations in PTX3 following aerobic exercise [12, 13, 17],
this review will address the possibility of utilizing aerobic
exercise as a nonpharmacological anti-inﬂammatory treat-
ment strategy to enhance plasma PTX3 concentrations in
obese individuals.
2. Structure and Function of Pentraxin
Superfamily
Pentraxins are an evolutionarily conserved superfamily of
proteins [18], identiﬁed by a 203 amino acid long “pentra-
xin domain” consisting of the His-x-Cys-x-Ser/Thr-Trp-x-
Ser amino acid sequence in the carboxy-terminal region,
where x is any amino acid [19–22]. Elucidation of the
structural characteristics has led to the organization of
pentraxins into two groups, the short and the long pentra-
xins, based on the N-terminal domain that is attached to
the pentraxin domain [21].
2.1. Short Pentraxins. Short pentraxins consist of C-reactive
protein (CRP) and serum amyloid P component (SAP). First
identiﬁed in 1930, elevated concentrations of CRP, then
termed fraction C, were observed in patients during the acute
stage of pneumococcus infection and remained depending
on the presence and severity of illness [23]. In 1941, MacLeod
and Avery referred to CRP as an “acute-phase reactant” to
describe its rapid accumulation in the blood following
inﬂammatory challenge [24]. CRP and SAP are now known
to be secreted primarily by the liver, and to lesser extents by
leukocytes, following stimulation by the proinﬂammatory
cytokine IL-6 [25–28]. Although baseline concentrations of
CRP typically do not exceed 2-3μg/mL, up to 1000-fold
increases in CRP are observed in response to a variety of
adverse inﬂammatory conditions, whereas SAP concentra-
tions remain relatively stable between 30 and 50μg/mL
[29]. These ﬁndings have contributed to the utilization of
CRP, but not SAP, as an indirect clinical marker of inﬂam-
matory disease status, particularly in cardiovascular disease
and metabolic dysregulation [30].
2.2. Long Pentraxins. Long pentraxins contain longer N-
terminal domains compared to their short pentraxin coun-
terparts and include, among others, pentraxin 3 (PTX3),
PTX4, and neutronal pentraxins 1 and 2. Of these, PTX3, also
known as TNF-stimulated gene (TSG-14), was the ﬁrst to be
discovered in 1990 and is the most well studied. PTX3 has a
molecular weight of ~42 kDa, is located on chromosome 3
(q25), consists of three exons, and contains a unique 178
amino acid long sequence which is structurally unique com-
pared to all other proteins [21, 31]. PTX3 was ﬁrst docu-
mented as an acute-phase reactant in 1992 [21] and is now
known to be evolutionarily conserved between murine and
human species, as protein sequences encoded by exon 1
and exon 2 share 93 and 81% structural homology, respec-
tively [32]. Furthermore, Breviario et al. [21] demonstrate
that vascular endothelial cell expression of PTX3 mRNA is
increased within 1 hour and peaks between 2 and 6 hours fol-
lowing stimulation with the proinﬂammatory cytokines IL-
1β and TNF-α, but not IL-6. Similarly, Lee et al. [31]
observed peak PTX3 mRNA expression levels in ﬁbroblasts
4 hours following IL-1β and TNF-α stimulation. Subsequent
analysis has conﬁrmed that PTX3 mRNA expression is elic-
ited in a variety of cell and tissue sources following stimula-
tion with IL-1β, TNF-α, and the proinﬂammatory stimulus
lipopolysaccharide (LPS) through activation of the nuclear
factor κB (NF-κB) and activator protein 1 (AP-1) transcrip-
tion factors [32, 33], including the lungs, ovaries, thymus,
brain, skeletal and cardiac muscle, visceral and subcutaneous
adipocytes, hepatocytes, monocytes and macrophages, den-
dritic cells, and neutrophils [7, 8, 11, 34–38]. In addition,
intravenous injection of LPS results in the elevation of sys-
temic PTX3 concentrations in both rodents and humans
[32, 35] due to activation of the PTX3 promotor genes within
the cell. The presence of a leader peptide of 17 amino acids
located in the N-terminus is essential for the secretion of pro-
tein [31]. Therefore, compared to CRP, the local expression
and concomitant systemic increase of circulating PTX3 that
occurs transiently in response to proinﬂammatory stimula-
tion suggests that PTX3 may be a more sensitive and viable
biomarker of tissue pathology and disease status.
3. PTX3 Dysregulation in Obesity
3.1. Obesity-Mediated Inﬂammation and Insulin Resistance.
Obesity is deﬁned as the excess accumulation of intra-
abdominal body fat which can be subdivided into two com-
partments: subcutaneous adipose tissue (SAT) and visceral
adipose tissue (VAT). While both tissue types are important,
evidence suggests that VAT is a stronger predictor of obesity-
related inﬂammation and metabolic disease [39, 40]. SAT
and VAT accumulation is a result of the increased number
and size of adipocytes [41, 42]. Analysis of adipocyte kinetics
indicates that the number of adipocytes increases more dra-
matically in obese compared to that in normal-weight indi-
viduals throughout childhood and plateaus upon reaching
adulthood, implying that further ﬂuctuations of adipose cell
mass are due to increased adipocyte hypertrophy resulting
from excess lipid storage [41].
Adipose tissue is not just a passive storage site for fat
accumulation but an endocrine organ contributing to the
production of anti-inﬂammatory and proinﬂammatory
proteins [43]. Adipocyte tissue consists of a mature adipo-
cyte fraction and a stromal-vascular fraction (SVF) com-
prised primarily of preadipocytes, vascular cells, and
leukocytes, including neutrophils and macrophages [44].
More speciﬁcally, neutrophils are rapidly recruited to the
SVF in response to acute, high-fat challenge (i.e., diet),
with peak concentrations occurring between 3 and 7 days
[1]. This acute inﬁltration of neutrophils precedes the
increased number of resident macrophages that accumu-
late within the SVF in response to as little as 8 weeks of
high-fat diet [1]. Macrophages are a heterogeneous cell
population which are roughly divided into two primary
phenotypes, classically activated (M1) and alternatively
activated (M2), based on their function and secretory
characteristics and are identiﬁed by their unique array of
cell surface markers [45, 46]. Macrophage phenotypes are
2 Mediators of Inﬂammation
largely determined by the microenvironment in which
they reside [46, 47]. For example, local concentrations of
the proinﬂammatory mediators LPS and interferon gamma
stimulate the polarization of M1 macrophages that are
responsible for the initiation of debris clearance and the
production of the proinﬂammatory cytokines IL-1β, IL-6,
and TNF-α, and the chemokine monocyte chemoattractant
protein 1 (MCP-1) [48]. Conversely, M2 macrophage polar-
ization is the result of IL-4 and IL-13 signaling [49]. In turn,
M2 macrophages produce the anti-inﬂammatory cytokines
IL-10 and TGF-β, which attenuate the proinﬂammatory
response and initiate tissue repair [49, 50].
During obesity, excess VAT hypertrophy is associated
with an increased concentration of macrophages [3]. In
fact, some estimates suggest that macrophages account
for up to 40% of the total nuclei content in adipose tissue
of obese individuals, compared to only 10% in that of
normal-weight individuals [3]. Furthermore, macrophages
in obese individuals are polarized toward an M1 pheno-
type and express elevated levels of proinﬂammatory
cytokine mRNA [3, 47]. To the contrary, resident adipose
tissue macrophages in normal-weight individuals are
primarily comprised of M2 macrophages which help the
cellular response counterregulates a proinﬂammatory chal-
lenge [47]. Interestingly, the distribution of macrophages is
also diﬀerent in obese compared to that in normal-weight
individuals. Weisberg et al. [3] demonstrate that macro-
phages in adipose tissue of lean mice are uniformly small
and widely dispersed among the adipocytes, whereas
macrophages from obese rodents are larger and gathered
in aggregate. More recent studies have shown that over
90% of resident macrophages are localized around adipo-
cytes that have died from lipid-induced cellular stress
(up to 15 per dead adipocyte) [39, 51]. Although visceral
adipocytes are about 20% smaller than subcutaneous
adipocytes, their capacity to expand is less, contributing
to an elevated rate (30-fold) of adipocyte cell death that
results in the localization of M1 macrophages in obese
individuals [39, 51].
The excess accumulation of M1 macrophages within
VAT is now understood to be the primary source of circulat-
ing proinﬂammatory cytokines IL-1β, IL-6, and TNF-α that
contribute to the state of chronic, low-grade inﬂammation
observed during obesity [3, 4]. M1 macrophages also express
and secrete the proinﬂammatory chemokine MCP-1 in
proportion to the amount of VAT, resulting in the enhanced
recruitment of circulating monocytes [52]. Bories et al. [46]
further report that the systemic proinﬂammatory environ-
ment observed during obesity predisposes circulating
monocytes toward a proinﬂammatory phenotype, and
upon entry into the adipose tissue, monocytes migrate to
the signaling site and preferentially diﬀerentiate into
resident M1 macrophages. These ﬁndings suggest that
the accumulation of M1 macrophages and increased
concentrations of macrophage-derived proinﬂammatory
proteins result in a positive feedback loop that further
exacerbates the local and systemic proinﬂammatory
milieu observed during obesity.
Studies also demonstrate that obesity-related
proinﬂammatory as a result of M1 macrophage accumula-
tion within VAT is associated with the number of metabolic
syndrome parameters [3, 53] and is directly linked with
the development and pathology of insulin resistance [4].
More speciﬁcally, macrophage-derived MCP-1, TNF-α,
and to a lesser extent IL-6 directly impair the mecha-
nisms involved with insulin-mediated glucose uptake in
adipose tissue and skeletal muscle [4, 54–58]. However,
neutralization of TNF-α and MCP-1 and the downregula-
tion of proinﬂammatory cytokine production restore
insulin-mediated glucose uptake in obese individuals
[58–61] and suggest that targeting the production of
macrophage-derived proinﬂammatory may positively reg-
ulate metabolic signaling.
3.2. PTX3 Expression in Obese Adipose Tissue. Abderrahim-
Ferkoune et al. [7] document that TNF-α elevates PTX3
mRNA expression in the SVF but not the mature adipocyte
fraction of adipose tissue in a dose-dependent manner. In
addition, Osorio-Conles et al. [11] demonstrate that IL-1β,
but not IL-6, contributes to PTX3 mRNA expression in adi-
pose tissue. In parallel with these ﬁndings, adipose tissue
expression of PTX3 mRNA is increased in obese compared
to that in normal-weight mice and is 3-fold higher in
diabetic-obese compared to that in nondiabetic obese mice
[7]. These ﬁndings suggest that disease pathology may fur-
ther enhance the expression of PTX3 mRNA in adipose tis-
sue; however, whether or not this is due to metabolic
dysregulation or the severity of proinﬂammatory status
remains unknown.
In humans, VAT expression of PTX3 mRNA is positively
associated with body mass index (BMI) [10] and is elevated
in obese and overweight (BMI > 25 kg/m2) compared to that
in normal-weight individuals (BMI 18.5–24.9 kg/m2) [11].
Furthermore, a positive association is observed between
PTX3 and IL-1β mRNA expression in VAT, as well as
TNF-α mRNA expression in SAT and VAT [10, 11]. How-
ever, greater PTX3 mRNA expression is reported in the
mature adipocyte, compared to the SVF [11]. In support of
these ﬁndings, Alberti et al. [10] report that PTX3 expression
in adipose tissue does not appear to follow the pattern of
macrophage distribution, as PTX3 mRNA expression is asso-
ciated with the macrophage-speciﬁc surface marker CD68 in
SAT, but not VAT, despite normal macrophage distribution
(VAT > SAT; obese > normal weight). These ﬁndings suggest
that adipose tissue components other than macrophages may
be responsible for the elevated expression of PTX3 mRNA
observed in obese humans.
In addition to inﬂammation, hyperinsulinemia, hypoxia,
and reactive oxygen species are linked to the dysregulation of
adipose tissue protein expression. However, human adipo-
cyte PTX3 mRNA expression is only slightly responsive to
hypoxic conditions and the mitochondrial complex II inhib-
itor antimycin [11], whereas H2O2 exposure results in a slight
downregulation of PTX3 mRNA, and insulin stimulation has
no eﬀect [11]. In addition, circulating low-density lipopro-
teins (LDL) are a predictor of PTX3 mRNA expression in
SAT of nondiabetic men [62], and high-density lipoproteins
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(HDL), which also regulate PTX3 mRNA expression in
endothelial cells [63], are an independent predictor of
PTX3 mRNA expression in VAT [10]. Therefore, addi-
tional research aimed at investigating the impact of circu-
lating cholesterol may provide insight into the factors that
contribute to elevated PTX3 mRNA expression in adipose
tissue during obesity.
3.3. Circulating PTX3 Concentrations during Obesity. Circu-
lating PTX3 concentrations are negatively associated with
numerous indices of obesity, including BMI, waist and hip
circumferences, and visceral fat mass (11, 67, 71, 86, 87, 99,
103), and positively associated with muscle mass (19). Anal-
ysis of daily ﬂuctuations of plasma PTX3 demonstrates that
systemic PTX3 concentrations are more stable compared to
CRP [64]. These observations have increased interest in uti-
lizing plasma PTX3 concentrations as a biomarker to assess
the severity of obesity-related inﬂammation and metabolic
disease. In contrast to the PTX3 mRNA expression patterns
observed in adipose tissue of obese individuals, reports on
plasma PTX3 concentrations in obese populations and in
those with metabolic dysregulation have yielded inconsistent
results. The majority of studies report that plasma PTX3 con-
centrations are lower in obese individuals and those with
metabolic dysregulation compared to that in normal-weight
and metabolically healthy controls [11–13, 62, 65–69]. To
the contrary, other studies report the opposite [70–72]; how-
ever, elevated PTX3 concentrations observed in these studies
may have been altered by the presence of atherosclerosis
which may diﬀerentially impact plasma PTX3 concentrations
in obese individuals. In fact, atherosclerosis induces a robust
proinﬂammatory response observed in both the vascular
endothelium and systemic circulation, and the parallel
increases in PTX3 expression and secretion may potentially
serve as protective mechanisms against the enhanced pro-
gression of atherosclerosis and associated proinﬂammatory
milieu [73, 74].
Importantly, circulating PTX3 concentrations are
impacted following weight loss intervention. Speciﬁcally,
short-term bed rest with caloric restriction (14 days) increases
plasma PTX3 concentrations in associationwith decreased fat
mass [75], while regression analysis demonstrates that a 1-
kilogram reduction in body weight is associated with a 74 pg/
mL increase in plasma PTX3 concentrations following a 6-
week dietary restriction intervention [69]. Witasp et al. [69]
further demonstrate that increased plasma PTX3 concentra-
tions are associated with reduced body weight, BMI, and cen-
tral adiposity over a 5-year observational period. Although
changes in metabolic parameters were not reported in these
studies, numerous studies report that lower resting PTX3 con-
centrations are negatively associated with circulating concen-
trations of proinﬂammatory cytokines, triglycerides, insulin,
glucose, and the HOMA-IR index of insulin resistance [11–
13, 65–67, 75] and incrementally lower with increased param-
eters ofmetabolic syndrome [65, 67]. PlasmaPTX3concentra-
tions are also negatively related with the insulin response
following intravenous and oral glucose administration [11],
and as Escobar-Morreale et al. [76] demonstrate, plasma
PTX3 decreases in response to oral glucose intake. However,
it remains unknown whether or not PTX3 decreases as a con-
sequence of metabolic dysfunction or if PTX3 provides a
mechanism to protect against the development of disease. A
recent study utilizing a diabetic-obese rat model reports that
in addition to lower circulating PTX3 concentrations, reduced
PTX3 mRNA expression is associated with the reduced
expression of the GLUT4 glucose transporter in skeletal mus-
cle [77].While theseﬁndingswereobservational innature, this
study suggests that PTX3may aid in the facilitation of glucose
homeostasis and highlights the need for additional research
aimed at investigating the mechanisms associated with
PTX3-mediated glucose uptake.
4. PTX3 as an Anti-Inflammatory Protein
4.1. Neutrophil Synthesis, Storage, and Release of PTX3. The
reasons for the paradoxical ﬁndings between adipose tissue
expression and systemic PTX3 concentrations are unclear,
and the tissue source responsible for regulating systemic
PTX3 concentrations is currently unknown. It is known that
maturing neutrophils, but not other polymorphonuclear cells
(basophils and eosinophils), synthesize and store ready-made
PTX3 within lactoferrin granules [8]. Interestingly, while
mature peripheral neutrophils do not express PTX3
mRNA or appear to be the primary source of systemic
PTX3 concentrations, mature neutrophils do release stored
PTX3 in response to LPS and TNF-α activation [8]. These
ﬁndings suggest that mature neutrophils are a reservoir
for PTX3 storage prior to their release in response to
proinﬂammatory challenge.
Evidence suggests that neutrophil counts and rates of
activation are increased in obese individuals and in those
with metabolic dysregulation [1, 2, 78, 79]. Given this, the
reduced concentrations of circulating PTX3 in these
populations may potentially reﬂect an impaired ability of
neutrophils to either synthesize PTX3 throughout their mat-
uration process or release stored PTX3 upon neutrophil
activation, posing deleterious risks during periods of inﬂam-
matory challenge. Conversely, it is also possible that reduced
PTX3 concentrations may reﬂect the increased release of
PTX3 by neutrophils within adipose tissue or increased
tissue uptake of PTX3 from circulation by a mechanism
currently unknown.
A novel study by Deban et al. [80] demonstrates that
PTX3 selectively binds the adhesion molecule P-selectin. Fol-
lowing inﬂammatory stimulation, P-selectin relocates to the
cell surface where it interacts with P-selectin glycoprotein
on leukocytes [81]. As a result, leukocytes are arrested at
the cell surface, inﬁltrate into the tissue, and stimulate a
heightened immune response [81]. Thus, the binding of
PTX3 to P-selectin aids in the regulation of the innate
immune response by limiting the cellular inﬁltration of neu-
trophils and monocytes [73, 80]. In addition, these ﬁndings
support the posit that PTX3 regulates the proinﬂammatory
milieu observed during obesity, potentially by attenuating
the inﬁltration of leukocytes into the adipose tissue.
4.2. Systemic Anti-Inﬂammatory Eﬀects of PTX3. In humans,
plasma PTX3 concentrations are inversely related to
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circulating proinﬂammatory cytokines (IL-6 and CRP) and
positively related with the anti-inﬂammatory cytokine IL-10
[75]. The initial studies investigating the role of PTX3 as a
mediator of inﬂammation utilized transgenic animal models
which overexpress PTX3. Speciﬁcally, researchers injected
the PTX3 transgenic mice with LPS and observed that
PTX3 mRNA expression was elevated in a variety of tissues,
including the heart and skeletal muscle, but not the liver
[82]. Following LPS injection, survival curve analysis further
revealed that transgenic expression of PTX3 rescued mice
from endotoxic shock and reduces symptoms of sepsis [82].
Furthermore, PTX3 transgenic mice possess elevated con-
centrations of the anti-inﬂammatory cytokine IL-10 and
exhibit a more robust anti-inﬂammatory response within
the ﬁrst few hours following LPS infusion [82].
Knockout animal models have also been utilized to dem-
onstrate the adverse consequences of low-PTX3 concentra-
tions. For example, Norata et al. [74] demonstrated that
PTX3 knockouts experience increased atherosclerotic lesion
size in the aorta, which was associated with the elevated
expression of proinﬂammatory cytokine mRNA and the
excess accumulation of macrophage within the atheroscle-
rotic plaque. In addition, increased risk of myocardial
infarction and elevated concentrations of circulating
proinﬂammatory cytokines, as well as excess neutrophil and
macrophage accumulation are observed in PTX3 knockout
mice [73, 83]. However, exogenous PTX3 administration
reversed this phenotype [73, 83], indicating that PTX3 is
necessary to regulate the appropriate immune response.
4.3. Cellular Anti-Inﬂammatory Eﬀects of PTX3. At the cellu-
lar level, proinﬂammatory stimulation by LPS is mediated by
the pattern recognition receptor toll-like receptor 4 (TLR4)
[84]. TLR4 is a transmembrane receptor which contains an
intracellular cytoplasmic region homologous to the IL-1
receptor termed the toll/IL-1R (TIR) domain [85]. Activation
of TLR4 signaling by LPS is reliant upon the action of two cell
surface accessory molecules: myeloid diﬀerentiation protein
2 (MD-2) and CD14 [86]. Following ligand binding, TLRs
undergo conformational changes resulting in the further
recruitment of the myeloid diﬀerentiation factor 88
(MyD88) and TIR-containing adaptor molecule (TRIF)
intracellular adaptor molecules that mediate the production
of proinﬂammatory cytokines and type I interferons, respec-
tively [87, 88]. Not surprisingly, TLR4 expression is elevated
in adipocytes and circulating leukocytes in obese individuals
and contributes to the increased risk of metabolic
dysregulation [89–91].
Recent studies have also begun to elucidate the anti-
inﬂammatory capacity of PTX3 at the cellular level. For
example, the PTX3 N-terminus binds MD-2 and inhibits
TLR4 activation in neutrophils, resulting in the reduced
inﬂammatory burden following fungal infection [15]. In
addition, activation of macrophages with high concentra-
tions of PTX3 (10ng/mL) attenuates LPS-induced produc-
tion of IL-1β, TNF-α, and MCP-1 by downregulating NF-
κB protein expression [14]. Furthermore, PTX3 increases
the production of the anti-inﬂammatory cytokines IL-10
and TGF-β through the Akt- and p38-mediated pathways,
respectively [14–16, 92]. Although the mechanisms responsi-
ble for the PTX3-mediated anti-inﬂammatory signaling have
not been fully elucidated, evidence suggests PTX3 signaling
acts through TLR2, 3, and 4, but not TLR9 engagement,
and is dependent upon TRIF-mediated activation of the
transcription factor interferon-regulated factor 3, but not
NF-κB [15, 92].
These ﬁndings suggest that PTX3 is a counterregulatory
protein which preferentially facilitates an anti-inﬂammatory
response by downregulating the production of neutrophil
and macrophage-derived proinﬂammatory proteins and
increasing the production of anti-inﬂammatory cytokines.
Thus, PTX3 may also facilitate the polarization of adipocyte
macrophages toward an M2 phenotype, as recently suggested
in diﬀerent tissue sources [93, 94]. Therefore, it is reasonable
to speculate that therapeutic approaches (i.e., weight loss,
regular physical exercise, and the potential development of
pharmacological interventions) which elevate circulating
PTX3 concentrations in obese individuals will help restore
obesity-related inﬂammatory imbalances and shift the sys-
temic and local inﬂammatory microenvironments to an
anti-inﬂammatory milieu.
5. PTX3 Response to Aerobic Exercise
Aerobic exercise training is an eﬀective therapeutic approach
against obesity-related proinﬂammatory and metabolic dys-
function. In fact, aerobic exercise training reduces adipocyte
size, elicits the polarization of macrophages toward an M2
phenotype, and lowers proinﬂammatory cytokine expression
in adipose tissue [95, 96]. As a result, the elevated local and
systemic anti-inﬂammatory proﬁles following aerobic exer-
cise training are associated with improved glucose metabo-
lism and protect against high-fat diet-induced insulin
resistance [96, 97].
Acute aerobic exercise also enhances systemic PTX3 con-
centrations. Our laboratory and others report that plasma
PTX3 concentrations are increased for up to 1 hour in
response to a single bout of aerobic exercise [12, 13, 17, 64].
Furthermore, Nakajima et al. [64] demonstrate that
exercise-induced plasma PTX3 concentrations are positively
associated with the neutrophil activation marker myeloper-
oxidase and that intracellular neutrophil concentrations of
PTX3 are reduced compared to resting values in response
to exercise in an intensity-dependent manner. These ﬁndings
suggest that neutrophils are a signiﬁcant source of elevated
PTX3 concentrations following acute aerobic exercise, poten-
tially serving as a mechanism to regulate the exercise-induced
neutrophil inﬁltration into the tissue. Similarly, regular par-
ticipation in aerobic exercise augments circulating concen-
trations of PTX3 at rest and in response to acute exercise.
More speciﬁcally, resting PTX3 concentrations are increased
in aerobically trained compared to that in sedentary males
[98], and cardiorespirtatory ﬁtness levels (VO2max) predict
the acute exercise-induced PTX3 response following sub-
maximal and maximal bouts of aerobic exercise [12, 13]. In
addition, plasma PTX3 concentrations increase after 8 weeks
of habitual moderate aerobic exercise training in elderly men
and women, and these increases are associated with elevated
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cardiorespiratory ﬁtness levels (VO2max) and improved indi-
ces of cardiovascular function [99, 100].
Data recently collected in our laboratory also demon-
strates that the capacity of acute exercise to increase plasma
PTX3 concentrations is similar in obese compared to that
in normal-weight individuals [12, 13], suggesting that a sin-
gle bout of aerobic exercise is equally beneﬁcial for obese
and normal-weight individuals. Furthermore, in response to
12 weeks of aerobic exercise training, elevated concentrations
of resting PTX3 in obese and overweight females were asso-
ciated with reductions in BMI [101]. From these results,
one might be tempted to hypothesize that increased PTX3
concentrations may also mediate the anti-inﬂammatory
eﬀects of aerobic exercise in obese individuals. However, no
associations have been observed between systemic PTX3
concentrations and indices of insulin resistance or
proinﬂammatory following acute aerobic exercise in our
laboratory [12, 13], suggesting that the cumulative eﬀects of
exercise training may be responsible for enhancing the anti-
inﬂammatory eﬀects of PTX3.
Unfortunately, only one study has investigated the rela-
tionship between PTX3 and indices of metabolic dysfunction
in response to physical activity intervention. As a result of
short-term physical activity intervention (7 days) in obese
adolescents, increased plasma PTX3 concentrations were
associated with decreased concentrations of circulating insu-
lin as well as the HOMA-IR index [67]. Although limited by
short duration, these ﬁndings provide evidence to warrant
additional research aimed at investigating the eﬀects of acute
and chronic aerobic exercise intervention on PTX3 concen-
trations in obese individuals.
6. Conclusion
The ﬁndings presented in this review demonstrate that PTX3
may be a potential target for demonstrating and understand-
ing the mechanistic impact of various therapies that address
obesity-related chronic inﬂammation and metabolic dys-
function. With the growing obesity epidemic and the long-
term health consequences of proinﬂammatory diseases, addi-
tional research focusing on the anti-inﬂammatory capacity of
PTX3 against inﬂammatory-mediated metabolic dysfunction
and the extent to which interventions such as weight loss
programs aerobic exercise, and pharmacological agents may
augment that these responses are necessary and warranted.
Conflicts of Interest
The authors declare that there is no conﬂict of interest
regarding the publication of this paper.
References
[1] V. Elgazar-Carmon, A. Rudich, N. Hadad, and R. Levy, “Neu-
trophils transiently inﬁltrate intra-abdominal fat early in the
course of high-fat feeding,” Journal of Lipid Research,
vol. 49, no. 9, pp. 1894–1903, 2008.
[2] Y. Herishanu, O. Rogowski, A. Polliack, and R. Marilus, “Leu-
kocytosis in obese individuals: possible link in patients with
unexplained persistent neutrophilia,” European Journal of
Haematology, vol. 76, no. 6, pp. 516–520, 2006.
[3] S. P. Weisberg, D. McCann, M. Desai, M. Rosenbaum,
R. L. Leibel, and A. W. Ferrante, “Obesity is associated with
macrophage accumulation in adipose tissue,” The Journal of
Clinical Investigation, vol. 112, no. 12, pp. 1796–1808, 2003.
[4] H. Xu, G. T. Barnes, Q. Yang et al., “Chronic inﬂammation in
fat plays a crucial role in the development of obesity-related
insulin resistance,” The Journal of Clinical Investigation,
vol. 112, no. 12, pp. 1821–1830, 2003.
[5] P. S. Patel, E. D. Buras, and A. Balasubramanyam, “The role
of the immune system in obesity and insulin resistance,”
Journal of Obesity, vol. 2013, Article ID 616193, p. 9, 2013.
[6] C. Ogden, M. Carroll, C. Fryar, and K. Flegal, “Prevalence of
obesity among adults and youth: United States, 2011-2014,”
NCHS Data Brief, vol. 219, no. 219, pp. 1–8, 2015.
[7] A. Abderrahim-Ferkoune, O. Bezy, C. Chiellini et al., “Char-
acterization of the long pentraxin PTX3 as a TNFα-induced
secreted protein of adipose cells,” Journal of Lipid Research,
vol. 44, no. 5, pp. 994–1000, 2003.
[8] S. Jaillon, G. Peri, Y. Delneste et al., “The humoral pattern
recognition receptor PTX3 is stored in neutrophil granules
and localizes in extracellular traps,” The Journal of Experi-
mental Medicine, vol. 204, no. 4, pp. 793–804, 2007.
[9] M. Imamura, T. Kawasaki, A. S. Savchenko et al., “Lipopoly-
saccharide induced expression of pentraxin 3 in human neu-
trophils and monocyte-derived macrophages,” Cellular
Immunology, vol. 248, no. 2, pp. 86–94, 2007.
[10] L. Alberti, L. Gilardini, A. Zulian et al., “Expression of long
pentraxin PTX3 in human adipose tissue and its relation with
cardiovascular risk factors,” Atherosclerosis, vol. 202, no. 2,
pp. 455–460, 2009.
[11] O. Osorio-Conles, M. Guitart, M. Chacón et al., “Plasma
PTX3 protein levels inversely correlate with insulin secretion
and obesity, whereas visceral adipose tissue PTX3 gene
expression is increased in obesity,” American Journal of Phys-
iology - Endocrinology and Metabolism, vol. 301, no. 6,
pp. E1254–E1261, 2011.
[12] A. L. Slusher, J. T. Mock, M. Whitehurst, A. Maharaj, and C.-
J. Huang, “The impact of obesity on pentraxin 3 and inﬂam-
matory milieu to acute aerobic exercise,” Metabolism, vol. 64,
no. 2, pp. 323–329, 2015.
[13] A. L. Slusher and C.-J. Huang, “Association of pentraxin 3
with insulin resistance and glucose response following maxi-
mal aerobic exercise in obese and normal-weight Individ-
uals,” Canadian Journal of Physiology and Pharmacology,
vol. 94, no. 7, pp. 734–738, 2016.
[14] A. Shiraki, N. Kotooka, H. Komoda, T. Hirase, J.-I. Oyama,
and K. Node, “Pentraxin-3 regulates the inﬂammatory activ-
ity of macrophages,” Biochemistry and Biophysics Reports,
vol. 5, pp. 290–295, 2016.
[15] S. Bozza, S. Campo, B. Arseni et al., “PTX3 binds MD-2 and
promotes TRIF-dependent immune protection in aspergillo-
sis,” The Journal of Immunology, vol. 193, no. 5, pp. 2340–
2348, 2014.
[16] A. L. Slusher, A. B. Mischo, and E. O. Acevedo, “Pentraxin 3
is an anti-inﬂammatory protein associated with lipid-induced
interleukin 10 in vitro,” Cytokine, vol. 86, pp. 36–40, 2016.
[17] C.-J. Huang, H. E. Webb, K. N. Beasley, D. A. McAlpine, S. E.
Tangsilsat, and E. O. Acevedo, “Cardiorespiratory ﬁtness
does not alter plasma pentraxin 3 and cortisol reactivity to
6 Mediators of Inﬂammation
acute psychological stress and exercise,” Applied Physiology,
Nutrition, and Metabolism, vol. 39, no. 3, pp. 375–380, 2013.
[18] M. Pepys and M. L. Baltz, “Acute phase proteins with special
reference to C-reactive protein and related proteins (pentax-
ins) and serum amyloid A protein,”Advances in Immunology,
vol. 34, pp. 141–212, 1983.
[19] E. B. de Oliveira, C. Gotschlich, and T. Liu, “Primary struc-
ture of human C-reactive protein,” Journal of Biological
Chemistry, vol. 254, no. 2, pp. 489–502, 1979.
[20] A. Bairoch, “PROSITE: a dictionary of sites and patterns
in proteins,” Nucleic Acids Research, vol. 19, pp. 2241–
2245, 1991.
[21] F. Breviario, E. M. d'Aniello, J. Golay et al., “Interleukin-1-
inducible genes in endothelial cells. Cloning of a new gene
related to C-reactive protein and serum amyloid P compo-
nent,” Journal of Biological Chemistry, vol. 267, no. 31,
pp. 22190–22197, 1992.
[22] J. Emsley, H. E. White, B. P. O'Hara et al., “Structure of pen-
tameric human serum amyloid P component,” Nature,
vol. 367, no. 6461, pp. 38–345, 1994.
[23] W. S. Tillett and T. Francis, “Serological reactions in pneu-
monia with a non-protein somatic fraction of pneumococ-
cus,” The Journal of Experimental Medicine, vol. 52, no. 4,
pp. 561–571, 1930.
[24] C. M. MacLeod and O. T. Avery, “The occurrence during
acute infections of a protein not normally present in the
blood III. Immunological properties of the C-reactive pro-
tein and its diﬀerentiation from normal blood proteins,”
The Journal of Experimental Medicine, vol. 73, no. 2,
pp. 191–200, 1941.
[25] J. Hurlimann, G. Thorbecke, and G. Hochwald, “The liver as
the site of C-reactive protein formation,” The Journal of
Experimental Medicine, vol. 123, no. 2, pp. 365–378, 1966.
[26] M. Pepys, M. L. Baltz, F. De Beer et al., “Biology of serum
amyloid P component,” Annals of the New York Academy of
Sciences, vol. 389, pp. 286–298, 1982.
[27] A. E. Kuta and L. L. Baum, “C-reactive protein is produced by
a small number of normal human peripheral blood lympho-
cytes,” The Journal of Experimental Medicine, vol. 164, no. 1,
pp. 321–326, 1986.
[28] J. V. Castell, M. J. Gómez-Lechón, M. David et al., “Interleu-
kin-6 is the major regulator of acute phase protein synthesis
in adult human hepatocytes,” FEBS Letters, vol. 242, no. 2,
pp. 237–239, 1989.
[29] M. Pepys, A. Dash, R. Markham, H. Thomas, B. Williams,
and A. Petrie, “Comparative clinical study of protein SAP
(amyloid P component) and C-reactive protein in serum,”
Clinical and Experimental Immunology, vol. 32, no. 1,
pp. 119–124, 1978.
[30] M. K. Rutter, J. B. Meigs, L. M. Sullivan, R. B. D’Agostino, and
P. W. Wilson, “C-reactive protein, the metabolic syndrome,
and prediction of cardiovascular events in the Framingham
oﬀspring study,” Circulation, vol. 110, no. 4, pp. 380–385,
2004.
[31] G.W. Lee, T. H. Lee, and J. Vilcek, “TSG-14, a tumor necrosis
factor-and IL-1-inducible protein, is a novel member of the
pentaxin family of acute phase proteins,” The Journal of
Immunology, vol. 150, no. 5, pp. 1804–1812, 1993.
[32] A. Altmeyer, L. Klampfer, A. R. Goodman, and J. Vilcek, “Pro-
moter structure and transcriptional activation of the murine
TSG-14 gene encoding a tumor necrosis factor/interleukin-1-
inducible pentraxin protein,” Journal of Biological Chemistry,
vol. 270, no. 43, pp. 25584–22590, 1995.
[33] A. Basile, A. Sica, E. d'Aniello et al., “Characterization of the
promoter for the human long pentraxin PTX3 role of NF-
κB in tumor necrosis factor-α and interleukin-1β regulation,”
Journal of Biological Chemistry, vol. 272, no. 13, pp. 8172–
8178, 1997.
[34] V. V. Alles, B. Bottazzi, G. Peri, J. Golay, M. Introna, and A.
Mantovani, “Inducible expression of PTX3, a new member
of the pentraxin family, in human mononuclear phagocytes,”
Blood, vol. 84, no. 10, pp. 3483–3493, 1994.
[35] G. W. Lee, A. R. Goodman, T. H. Lee, and J. Vilcek, “Rela-
tionship of TSG-14 protein to the pentraxin family of major
acute phase proteins,” The Journal of Immunology, vol. 153,
no. 8, pp. 3700–3707, 1994.
[36] M. Introna, V. V. Alles, M. Castellano et al., “Cloning of
mouse ptx3, a new member of the pentraxin gene family
expressed at extrahepatic sites,” Blood, vol. 87, no. 5,
pp. 1862–1872, 1996.
[37] N. Polentarutti, B. Bottazzi, E. Di Santo et al., “Inducible
expression of the long pentraxin PTX3 in the central nervous
system,” Journal of Neuroimmunology, vol. 106, no. 1-2,
pp. 87–94, 2000.
[38] A. Doni, M. Michela, B. Bottazzi et al., “Regulation of PTX3, a
key component of humoral innate immunity in human den-
dritic cells: stimulation by IL-10 and inhibition by IFN-γ,”
Journal of Leukocyte Biology, vol. 79, no. 4, pp. 797–802, 2006.
[39] I. Murano, G. Barbatelli, V. Parisani et al., “Dead adipocytes,
detected as crown-like structures, are prevalent in visceral fat
depots of genetically obese mice,” Journal of Lipid Research,
vol. 49, no. 7, pp. 1562–1568, 2008.
[40] A. Veilleux, M. Caron-Jobin, S. Noël, P. Y. Laberge, and
A. Tchernof, “Visceral adipocyte hypertrophy is associ-
ated with dyslipidemia independent of body composition
and fat distribution in women,” Diabetes, vol. 60, no. 5,
pp. 1504–1511, 2011.
[41] K. L. Spalding, E. Arner, P. O. Westermark et al., “Dynamics
of fat cell turnover in humans,” Nature, vol. 453, no. 7196,
pp. 783–787, 2008.
[42] A. Tchernof and J.-P. Després, “Pathophysiology of human
visceral obesity: an update,” Physiological Reviews, vol. 93,
no. 1, pp. 359–404, 2013.
[43] S. Galic, J. S. Oakhill, and G. R. Steinberg, “Adipose tissue as
an endocrine organ,” Molecular and Cellular Endocrinology,
vol. 316, no. 2, pp. 129–139, 2010.
[44] M. E. Trujillo and P. E. Scherer, “Adipose tissue-derived fac-
tors: impact on health and disease,” Endocrine Reviews,
vol. 27, no. 7, pp. 762–778, 2006.
[45] R. D. Stout, C. Jiang, B. Matta, I. Tietzel, S. K. Watkins,
and J. Suttles, “Macrophages sequentially change their
functional phenotype in response to changes in microenvi-
ronmental inﬂuences,” The Journal of Immunology,
vol. 175, no. 1, pp. 342–349, 2005.
[46] G. Bories, R. Caiazzo, B. Derudas et al., “Impaired alternative
macrophage diﬀerentiation of peripheral blood mononuclear
cells from obese subjects,” Diabetes & Vascular Disease
Research, vol. 9, no. 3, pp. 189–195, 2012.
[47] C. N. Lumeng, J. L. Bodzin, and A. R. Saltiel, “Obesity induces
a phenotypic switch in adipose tissue macrophage polariza-
tion,” The Journal of Clinical Investigation, vol. 117, no. 1,
pp. 175–184, 2007.
7Mediators of Inﬂammation
[48] F. O. Martinez and S. Gordon, “The M1 and M2 paradigm of
macrophage activation: time for reassessment,” F1000Prime
Rep, vol. 6, no. 13.10, p. 12703, 2014.
[49] S. Gordon, “Alternative activation of macrophages,” Nature
Reviews Immunology, vol. 3, no. 1, pp. 23–35, 2003.
[50] N. G. Frangogiannis, “Regulation of the inﬂammatory
response in cardiac repair,” Circulation Research, vol. 110,
no. 1, pp. 159–173, 2012.
[51] S. Cinti, G. Mitchell, G. Barbatelli et al., “Adipocyte death
deﬁnes macrophage localization and function in adipose tis-
sue of obese mice and humans,” Journal of Lipid Research,
vol. 46, no. 11, pp. 2347–2355, 2005.
[52] R. Yu, C. S. Kim, B. S. Kwon, and T. Kawada, “Mesenteric
adipose tissue-derived monocyte chemoattractant protein-1
plays a crucial role in adipose tissue macrophage migration
and activation in obese mice,” Obesity, vol. 14, no. 8,
pp. 1353–1362, 2006.
[53] I. Harman-Boehm, M. Blüher, H. Redel et al., “Macrophage
inﬁltration into omental versus subcutaneous fat across dif-
ferent populations: eﬀect of regional adiposity and the
comorbidities of obesity,” The Journal of Clinical Endocrinol-
ogy & Metabolism, vol. 92, no. 6, pp. 2240–2247, 2007.
[54] G. S. Hotamisligil, N. S. Shargill, and B. M. Spiegelman, “Adi-
pose expression of tumor necrosis factor-alpha: direct role in
obesity-linked insulin resistance,” Science, vol. 259, no. 5091,
pp. 87–91, 1993.
[55] G. S. Hotamisligil, D. L. Murray, L. N. Choy, and B. M. Spie-
gelman, “Tumor necrosis factor alpha inhibits signaling from
the insulin receptor,” Proceedings of the National Academy of
Sciences, vol. 91, no. 11, pp. 4854–4858, 1994.
[56] G. S. Hotamisligil, P. Peraldi, A. Budavari, R. Ellis, M. F.
White, and B. M. Spiegelman, “IRS-1-mediated inhibition
of insulin receptor tyrosine kinase activity in TNF-α-and
obesity-induced insulin resistance,” Science, vol. 271,
no. 5249, pp. 665–670, 1996.
[57] V. Rotter, I. Nagaev, and U. Smith, “Interleukin-6 (IL-6)
induces insulin resistance in 3T3-L1 adipocytes and is, like
IL-8 and tumor necrosis factor-α, overexpressed in human
fat cells from insulin-resistant subjects,” Journal of Biological
Chemistry, vol. 278, no. 46, pp. 45777–45784, 2003.
[58] P. Sartipy and D. J. Loskutoﬀ, “Monocyte chemoattractant
protein 1 in obesity and insulin resistance,” Proceedings of
the National Academy of Sciences, vol. 100, no. 12,
pp. 7265–7270, 2003.
[59] H. Kanda, S. Tateya, Y. Tamori et al., “MCP-1 contributes to
macrophage inﬁltration into adipose tissue, insulin resis-
tance, and hepatic steatosis in obesity,” The Journal of
Clinical Investigation, vol. 116, no. 6, pp. 1494–1505, 2006.
[60] N. Kamei, K. Tobe, R. Suzuki et al., “Overexpression of
monocyte chemoattractant protein-1 in adipose tissues
causes macrophage recruitment and insulin resistance,” Jour-
nal of Biological Chemistry, vol. 281, no. 36, pp. 26602–26614,
2006.
[61] K. T. Uysal, S. M. Wiesbrock, M. W. Marino, and
G. S. Hotamisligil, “Protection from obesity-induced insulin
resistance in mice lacking TNF-α function,” Nature,
vol. 389, no. 6651, pp. 610–614, 1997.
[62] A. Bosutti, G. Grassi, M. Zanetti et al., “Relation between the
plasma levels of LDL-cholesterol and the expression of the
early marker of inﬂammation long pentraxin PTX3 and the
stress response gene p66 (ShcA) in pacemaker-implanted
patients,” Clinical and Experimental Medicine, vol. 7, no. 1,
pp. 16–23, 2007.
[63] G. D. Norata, P. Marchesi, A. Pirillo et al., “Long pentraxin 3,
a key component of innate immunity, is modulated by high-
density lipoproteins in endothelial cells,” Arteriosclerosis,
Thrombosis, and Vascular Biology, vol. 28, no. 5, pp. 925–
931, 2008.
[64] T. Nakajima, M. Kurano, T. Hasegawa et al., “Pentraxin3 and
high-sensitive C-reactive protein are independent inﬂamma-
tory markers released during high-intensity exercise,” Euro-
pean Journal of Applied Physiology, vol. 110, no. 5, pp. 905–
913, 2010.
[65] K. Yamasaki, M. Kurimura, T. Kasai, M. Sagara, T. Kodama,
and K. Inoue, “Determination of physiological plasma pen-
traxin 3 (PTX3) levels in healthy populations,” Clinical
Chemistry and Laboratory Medicine, vol. 47, no. 4, pp. 471–
477, 2009.
[66] T. Ogawa, Y. Kawano, T. Imamura et al., “Reciprocal con-
tribution of pentraxin 3 and C-reactive protein to obesity
and metabolic syndrome,” Obesity, vol. 18, no. 9,
pp. 1871–1874, 2010.
[67] S. H. Chu, J.-H. Park, M. K. Lee et al., “The association
between pentraxin 3 and insulin resistance in obese children
at baseline and after physical activity intervention,” Clinica
Chimica Acta, vol. 413, no. 19-20, pp. 1430–1437, 2012.
[68] A. Miyaki, S. Maeda, Y. Choi et al., “Association of plasma
pentraxin 3 with arterial stiﬀness in overweight and obese
individuals,” American Journal of Hypertension, vol. 26,
no. 10, pp. 1250–1255, 2013.
[69] A. Witasp, J. J. Carrero, K. Michaëlsson et al., “Inﬂammatory
biomarker pentraxin 3 (PTX3) in relation to obesity, body fat
depots and weight loss,” Obesity, vol. 22, no. 5, pp. 1373–
1379, 2014.
[70] M. Zanetti, A. Bosutti, C. Ferreira et al., “Circulating pentra-
xin 3 levels are higher in metabolic syndrome with subclinical
atherosclerosis: evidence for association with atherogenic
lipid proﬁle,” Clinical and Experimental Medicine, vol. 9,
no. 3, pp. 243–248, 2009.
[71] A. Miyaki, S. Maeda, M. Yoshizawa et al., “Is pentraxin 3
involved in obesity-induced decrease in arterial distensibil-
ity?” Journal of Atherosclerosis and Thrombosis, vol. 17,
no. 3, pp. 278–284, 2010.
[72] M. F. Karakas, E. Buyukkaya, M. Kurt et al., “Serum
pentraxin-3 levels are associated with the severity of meta-
bolic syndrome,” Medical Principles and Practice, vol. 22,
no. 3, pp. 274–279, 2012.
[73] M. Salio, S. Chimenti, N. De Angelis et al., “Cardioprotective
function of the long pentraxin PTX3 in acute myocardial
infarction,” Circulation, vol. 117, no. 8, pp. 1055–1064, 2008.
[74] G. D. Norata, P. Marchesi, V. K. P. Venu et al., “Deﬁciency of
the long pentraxin PTX3 promotes vascular inﬂammation
and atherosclerosis,” Circulation, vol. 120, no. 8, pp. 699–
708, 2009.
[75] A. Bosutti, G. Malaponte, M. Zanetti et al., “Calorie restric-
tion modulates inactivity-induced changes in the inﬂamma-
tory markers C-reactive protein and pentraxin-3,” The
Journal of Clinical Endocrinology & Metabolism, vol. 93,
no. 8, pp. 3226–3229, 2008.
[76] H. F. Escobar-Morreale, M. Á. Martínez-García, R. Montes-
Nieto, E. Fernández-Durán, S. Temprano-Carazo, and M.
Luque-Ramírez, “Eﬀects of glucose ingestion on circulating
8 Mediators of Inﬂammation
inﬂammatory mediators: Inﬂuence of sex and weight excess,”
Clinical Nutrition, vol. 36, no. 2, pp. 522–529, 2016.
[77] A. Miyaki, Y. Choi, and S. Maeda, “Pentraxin 3 production in
the adipose tissue and the skeletal muscle in diabetic-obese
mice,” The American Journal of the Medical Sciences,
vol. 347, no. 3, pp. 228–233, 2014.
[78] H. Kaur, B. Adams-Huet, G. Smith, and I. Jialal, “Increased
neutrophil count in nascent metabolic syndrome,” Metabolic
Syndrome and Related Disorders, vol. 11, no. 2, pp. 128–131,
2013.
[79] E. Buyukkaya, M. F. Karakas, E. Karakaş et al., “Correlation of
neutrophil to lymphocyte ratio with the presence and severity
of metabolic syndrome,” Clinical and Applied Thrombosis/
Hemostasis, vol. 20, no. 2, pp. 159–163, 2012.
[80] L. Deban, R. C. Russo, M. Sironi et al., “Regulation of leuko-
cyte recruitment by the long pentraxin PTX3,”Nature Immu-
nology, vol. 11, no. 4, pp. 328–334, 2010.
[81] J. Yang, T. Hirata, K. Croce et al., “Targeted gene disruption
demonstrates that P-selectin glycoprotein ligand 1 (PSGL-1)
is required for P-selectin-mediated but not E-selectin-
mediated neutrophil rolling and migration,” The Journal of
Experimental Medicine, vol. 190, no. 12, pp. 1769–1782, 1999.
[82] A. A. Dias, A. R. Goodman, J. L. Dos Santos et al., “TSG-14
transgenic mice have improved survival to endotoxemia
and to CLP-induced sepsis,” Journal of Leukocyte Biology,
vol. 69, no. 6, pp. 928–936, 2001.
[83] T. Shimizu, S. Suzuki, A. Sato et al., “Cardio-protective eﬀects
of pentraxin 3 produced from bone marrow-derived cells
against ischemia/reperfusion injury,” Journal of Molecular
and Cellular Cardiology, vol. 89, no. Pt B, pp. 306–313, 2015.
[84] E. M. Pålsson-McDermott and L. A. O’Neill, “Signal trans-
duction by the lipopolysaccharide receptor, toll-like recep-
tor-4,” Immunology, vol. 113, no. 2, pp. 153–162, 2004.
[85] A. Bowie and L. O'Neill, “The interleukin-1 receptor/toll-like
receptor superfamily: signal generators for proinﬂammatory
interleukins and microbial products,” Journal of Leukocyte
Biology, vol. 67, no. 4, pp. 508–514, 2000.
[86] S. D. Wright, R. A. Ramos, P. S. Tobias, R. J. Ulevitch, and
J. C. Mathison, “CD14, a receptor for complexes of lipo-
polysaccharide (LPS) and LPS binding protein,” Science,
vol. 249, no. 4975, pp. 1431–1433, 1990.
[87] T. Kawai, O. Adachi, T. Ogawa, K. Takeda, and S. Akira,
“Unresponsiveness of MyD88-deﬁcient mice to endotoxin,”
Immunity, vol. 11, no. 1, pp. 115–122, 1999.
[88] M. Yamamoto, S. Sato, H. Hemmi et al., “Role of adaptor
TRIF in the MyD88-independent toll-like receptor signaling
pathway,” Science, vol. 301, no. 5633, pp. 640–643, 2003.
[89] R. Ahmad, A. Al-Mass, V. Atizado et al., “Elevated expression
of the toll like receptors 2 and 4 in obese individuals: its sig-
niﬁcance for obesity-induced inﬂammation,” Journal of
Inﬂammation, vol. 9, no. 1, p. 48, 2012.
[90] I. Jialal, B. A. Huet, H. Kaur, A. Chien, and S. Devaraj,
“Increased toll-like receptor activity in patients withmetabolic
syndrome,”Diabetes Care, vol. 35, no. 4, pp. 900–904, 2012.
[91] V. Catalan, J. Gomez-Ambrosi, A. Rodríguez et al.,
“Increased tenascin C and toll-like receptor 4 levels in visceral
adipose tissue as a link between inﬂammation and extracellu-
lar matrix remodeling in obesity,” The Journal of Clinical
Endocrinology & Metabolism, vol. 97, no. 10, pp. E1880–
E1889, 2012.
[92] S. Bozza, F. Bistoni, R. Gaziano et al., “Pentraxin 3 protects
fromMCMV infection and reactivation through TLR sensing
pathways leading to IRF3 activation,” Blood, vol. 108, no. 10,
pp. 3387–3396, 2006.
[93] S. Pucci, T. Fisco, M. Zonetti, E. Bonanno, P. Mazzarelli, and
A. Mauriello, “PTX3: a modulator of human coronary plaque
vulnerability acting by macrophages type 2,” International
Journal of Cardiology, vol. 176, no. 3, pp. 710–717, 2014.
[94] H. Sun, J. Tian, W. Xian, T. Xie, and X. Yang, “Pentraxin-3
attenuates renal damage in diabetic nephropathy by promot-
ing M2 macrophage diﬀerentiation,” Inﬂammation, vol. 38,
no. 5, pp. 1739–1747, 2015.
[95] K. S. Gollisch, J. Brandauer, N. Jessen et al., “Eﬀects of exer-
cise training on subcutaneous and visceral adipose tissue in
normal- and high-fat diet-fed rats,” American Journal of
Physiology - Endocrinology and Metabolism, vol. 297, no. 2,
pp. E495–E504, 2009.
[96] M. A. Linden, Y. Pincu, S. A. Martin, J. A. Woods, and
T. Baynard, “Moderate exercise training provides modest
protection against adipose tissue inﬂammatory gene expres-
sion in response to high-fat feeding,” Physiological Reports,
vol. 2, no. 7, article e12071, 2014.
[97] V. J. Vieira, R. J. Valentine, K. R. Wilund, N. Antao, T.
Baynard, and J. A. Woods, “Eﬀects of exercise and low-
fat diet on adipose tissue inﬂammation and metabolic
complications in obese mice,” American Journal of Physiology
- Endocrinology and Metabolism, vol. 296, no. 5, pp. E1164–
E1171, 2009.
[98] A. Miyaki, S. Maeda, T. Otsuki, and R. Ajisaka, “Plasma pen-
traxin3 concentration increases in endurance-trained men,”
Medicine and Science in Sports and Exercise, vol. 43, no. 1,
pp. 12–17, 2011.
[99] A. Miyaki, S. Maeda, Y. Choi, N. Akazawa, Y. Tanabe, and R.
Ajisaka, “Habitual aerobic exercise increases plasma pentra-
xin 3 levels in middle-aged and elderly women,” Applied
Physiology, Nutrition, and Metabolism, vol. 37, no. 5,
pp. 907–911, 2012.
[100] A. Zempo-Miyaki, S. Fujie, K. Sato et al., “Elevated pentraxin
3 level at the early stage of exercise training is associated with
reduction of arterial stiﬀness in middle-aged and older
adults,” Journal of Human Hypertension, vol. 30, no. 9,
pp. 521–526, 2015.
[101] A. Miyaki, S. Maeda, Y. Choi et al., “The addition of whole-
body vibration to a lifestyle modiﬁcation on arterial stiﬀness
in overweight and obese women,” Artery Research, vol. 6,
no. 2, pp. 85–91, 2012.
9Mediators of Inﬂammation
Submit your manuscripts at
https://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
